Boehringer Ingelheim said the FDA approved the supplemental biologics license application for Cyltezo as the first Interchangeable biosimilar with Humira.
- The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases and this latest approval designates it as Interchangeable across all of these indications
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used with permission.